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RESUMO – O melanoma é o cancro cutâneo mais comum da idade pediátrica. No entanto, é extremamente raro nesta popula-
ção, sendo ainda mais raro nas crianças com menos de 11 anos. O diagnóstico é frequentemente difícil, devido à sua raridade 
e apresentações atípicas.
Existem três subtipos de melanoma em idade pediátrica: melanoma Spitzoide; melanoma que emerge de nevo melanocítico 
congénito e o melanoma convencional. O melanoma congénito pode ocorrer, embora seja excepcionalmente raro, não cons-
tituindo um subtipo distinto de melanoma. O melanoma Spitzoide é o subtipo mais comum que afecta crianças com idade 
inferior a 11 anos. Embora apresente características locais agressivas, com envolvimento ganglionar frequente, acarreta um 
prognóstico excelente. A ocorrência de transformação maligna de nevos melanocíticos congénitos apresenta uma grande varia-
bilidade, de acordo com a sua dimensão, número e afeção concomitante do sistema nervoso central. A vigilância e tratamento 
desta transformação maligna é problemática, sendo associada a pobres resultados. Nos adolescentes, o subtipo de melanoma 
mais comum é o convencional (tipo adulto). Contrariamente à população adulta, a maioria dos melanomas pediátricos con-
vencionais tem origem em nevos pré-existentes, seguindo a epidemiologia e factores de risco associados ao do adulto. Não 
existem orientações específicas para a gestão e tratamento do melanoma pediátrico, pelo que esta doença é tratada de forma 
semelhante ao melanoma do adulto. 
PALAVRAS-CHAVE – Criança; Melanoma/diagnóstico; Melanoma/epidemiologia; Melanoma/etiologia; Melanoma/trata-
mento; Nevo de Células Epitelioides e Fusiformes; Nevo Pigmentado.
Pediatric Melanoma: Epidemiology, Pathogenesis, 
Diagnosis and Management 
ABSTRACT – Pediatric melanoma is the most common skin cancer in children. However, it is extremely rare this population, being 
even rarer in younger than 10 years of age. Its diagnosis is often difficult, due to its rarity and atypical presentations. 
There are three main subtypes of pediatric melanoma: Spitzoid melanoma, melanoma arising in a congenital melanocytic nevus 
and conventional melanoma. Congenital melanomas exist and are exceptionally rare, although they do not constitute a different 
subtype of melanoma. Spitzoid melanoma is the most common subtype affecting children younger than 11 years. Despite presen-
ting with local aggressive features and frequent nodal involvement, it encompasses an excellent prognosis. The risk of malignant 
transformation of congenital melanocytic nevi varies widely accordingly to the projected adult size, number, and concomitant ab-
normalities found in the central nervous system. The surveillance and treatment of melanoma arising in a congenital melanocytic 
nevus is challenging, enclosing poor outcomes. In adolescents, the most common subtype is the conventional (adult-type). Contrary 
to the adult population, the majority of conventional pediatric melanoma arises from previous nevi but follows the general adult 
epidemiology and risk factors. Specific guidelines for management of pediatric melanoma do not exist and it is treated similarly 
to melanoma in the adult.  
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Cutaneous melanoma is a common malignancy in 
adults,1 responsible for the majority of the deaths caused 
by skin cancer. Its overall frequency is increasing worldwi-
de,2 with an annual incidence rate of 20 per 100 000 peo-
ple.1 In spite of being the most common skin cancer in the 
pediatric population and accounting for 7% of all cancers 
in 15-19 year old age group,3 it is extremely uncommon 
in this population. Less than 1% of all melanomas occur in 
patients younger than 20 years old,4 less than 0.4% occur 
in prepubertal patients5 and only 0.1% in patients younger 
than 10 years of age.6 According to the European Coope-
rative Study Group for Pediatric Rare Tumors that defines 
tumors as rare if their incidence is below 1 case/million/
year, melanoma is considered rare below 10 years of age 
(0.7-0.8 cases/million/year) but not between 15-19 years 
(>10 cases/million/year).1 The average age of diagnosis 
is 13.3 years.6 Though the incidence of melanoma in chil-
dren younger than 10 years has remained stable, the in-
cidence in adolescents is increasing at a rate of 2.9% per 
year, in the USA over the past 3 decades.7
Several risk factors for pediatric melanomas have been 
identified. Albeit no considerable sex-based differences are 
verified in the 0-9 group, an increasing disparity between 
genders – with higher risk towards white females - is found 
through adolescence into early adulthood.8 A similar va-
riance is observed in the relationship between Fitzpatri-
ck phototypes and age, as melanoma incidence between 
white and non-white ethnicities starts slowly to diverge by 
5–9 years of age, ultimately reaching a 40-fold higher risk 
in the former by the age of 20.9 Ultraviolet light exposure, 
mostly due to sunlight, is especially linked with the develo-
pment of melanomas in white adolescents. A high number 
of moles (>100 with >2 mm diameter) is regarded as the 
strongest risk factor in this population.10 Preexisting con-
ditions known to be associated with melanoma (dysplastic 
nevus syndrome, congenital melanocytic nevi (CMN), xe-
roderma pigmentosa, immunodeficiency, prior malignancy 
and radiation therapy) seem to be more prevalent in chil-
dren up to 10 years of age10,11 Familial cases account for 
1% of pediatric melanomas.10 
 Pediatric melanoma presents a clinical and histopa-
thological challenge due to its rarity and atypical presenta-
tions. Up to 60% of diagnoses in patients younger than 10 
years and 40% in patients with 11–19 years do not meet 
traditional ABCDE criteria (asymmetry, border irregularity, 
color variation, diameter > 6 mm and evolution).5 A mo-
dified ABCDE criteria was proposed to evaluate suspicious 
skin lesions in children and adolescents: amelanotic, blee-
ding or bump, color uniformity, de novo and any diame-
ter, and evolution.5 Due to the tendency to be amelanotic, 
pediatric melanoma can be, in a first stage, misdiagnosed 
with benign skin lesions.5,10 Pediatric melanoma appears 
to have a more favorable prognosis than adult melanoma 
of a similar stage, with a 10 years overall survival of 70% 
to 80%.7
2. PEDIATRIC MELANOMA SUBTYPES
Melanomas affecting the pediatric age can be classified 
in three subtypes: Spitzoid melanoma, melanoma arising in 
congenital melanocytic nevi (CMN), and conventional (adult-
-type) melanoma. In general,  melanomas presenting in chil-
dren younger than 11 years have higher rates of ulceration, 
thickness, mitotic activity and positive sentinel lymph nodes, 
albeit this findings do not translate into higher mortality 
rates.9 Moreover, they are more often located on the head 
and neck region and on the extremities and belong to the 
Spitzoid subtype.9,12 In adolescents (≥11 years), conventio-
nal melanoma is the prevailing subtype,13 which shares mor-
phologic (superficial spreading and nodular) and molecular 
features with adult melanoma and is mainly located on the 
trunk.4,12 Acral lentiginous melanoma and lentigo maligna 
types are exceedingly rare.9 Melanomas can also develop in 
uterus, although this is extremely rare and does not constitute 
a different subtype of melanoma.
2.1. Spitzoid melanoma
2.1.1 Epidemiology and pathogenesis
The Spitzoid tumors encompass a biologic spectrum of 
spindle and epithelioid melanocytic proliferations which in-
clude the Spitz tumor without atypia (classic Spitz nevus), the 
atypical Spitz tumor and the Spitzoid melanoma.14 Most Spitz 
nevi do not evolve into melanoma.15 Although Spitzoid tu-
mors can affect all age groups, they usually arise during chil-
dhood or adolescence. 
Spitzoid melanomas are the most common subtype 
of melanoma found in patients younger than 11 years of 
age.9,15 As such, environmental exposures and UVR are like-
ly to have a small role in their development; in most cases, 
chromosomal structural rearrangements are the initiating 
genomic event. Mutations affecting the most commonly in-
volved genes (ROS1, NTRK1, NTRK3, ALK, BRAF, MAPK, MET, 
RET) have been observed in more than half of Spitzoid neo-
plasms. The result is the production of aberrant fusion pro-
teins, which constitutively activate and stimulate oncogenic 
pathways. These genomic fusions are observed across the 
spectrum of Spitzoid tumors, highlighting that they are not 
indicative of malignant behavior.9 By contrast, homozygous 
deletions in chromosome 9p21 have been linked to Spitzoid 
melanoma with an increased risk of advanced disease, dis-
tant metastases, and death.16 TERT promoter mutations are 
usually absent and their presence is highly correlated with 
the development of metastatic disease.17 The presence of 
such mutations worsens the outcome of patients with Spit-
zoid neoplasms, although they still seem to have a better 
prognosis than similarly staged conventional melanomas.18 
Typically, BRAF or NRAS mutations do not occur in Spitzoid 
tumors.13
2.1.2 Diagnosis
Clinically, Spitzoid tumors present as a deeply pigmented 
or amelanotic, pink / reddish, flat- or dome-shaped papule 
or nodule, located on the head, neck and distal extremities. 
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Three dermoscopic patterns are suggestive of a Spitz nevus: 
starburst pattern, regularly distributed dotted vessels and 
globular pattern with reticular depigmentation.19 Dermos-
copically asymmetric lesions with spitzoid features should be 
excised, in any age, to rule out melanoma.9,19 All spitzoid-
-looking nodules and lesions developing after the age of 12 
years should also be considered for excision. On the other 
hand, a symmetrically looking spitzoid lesion, below the age 
of 12 years can usually be safely followed up, as the proba-
bility of being a melanoma is extremely low.19 On histology, 
Spitzoid melanomas present abundant eosinophilic cyto-
plasm, high degree of nuclear atypia, with ulceration, epi-
dermal consumption, brisk deep atypical mitotic activity, and 
poor maturation.9 The distinction between benign Spitzoid tu-
mors and Spitzoid melanomas can be challenging and clini-
cal, morphological and molecular criteria must be employed 
by an expert dermatopathologist.9,19,20 Immunohistochemical 
assays for BRAF and NRAS can be performed, and the pre-
sence of these mutations support the diagnosis of a conven-
tional melanoma.9 A novel technique, using imaging mass 
spectrometry, discriminated correctly Spitz nevi from Spitzoid 
melanomas with 97% sensitivity and 90% specificity, although 
this approach has not yet been clinically validated.21
 
2.1.3 Management
At the time of the excision, Spitzoid melanomas tend to 
be advanced, usually presenting with a higher Breslow depth 
and mitotic activity, as well as more frequent nodal disease. 
Nevertheless, their overall prognosis is excellent (five-year 
survival higher than 95%).9 Thus, the decision to perform a 
sentinel lymph node biopsy (SLNB) should be considered ca-
refully.9 In a systematic review published in 2014,22 including 
541 patients with atypical Spitz tumours, SLNB performed in 
more than half of the patients (n= 303; 56%)  was positive 
in 119 (39%). When comparing the group of patients who 
had positive SLNB and the patients who were treated with 
wide local excision alone, no significant difference in survival 
was recorded and 99% of the patients did not show disease 
progression in a 5-years follow-up.22 Due to the uncertain 
prognostic potential of SLNB, limited benefit of lymph node 
dissections and high morbidity potential, management of an 
atypical spitzoid tumor should be limited to a wide local ex-
cision and long-term follow-up. 
2.2. Melanoma arising in CMN
2.2.1 Epidemiology and pathogenesis
CMN affect approximately 1% of neonates.9 They are 
classified, according to their projected adult size (PAS), as 
small (< 1.5 cm), medium (1.5-20 cm) and large or giant 
(>20 cm).9,23,24 Giant CMN are present in only 1/20 000 
infants and are usually associated with other smaller CMN.23 
CMNs are the result of a somatic mutation in utero, lea-
ding into a mosaicism.23 If the mutation occurs early, it can 
hit a multipotent cell, leading into multiple cutaneous CMN, 
with variable sizes and potential involvement of other organ 
systems.23 Giant or multiple CMN are often complicated by 
the presence of neurological abnormalities (e.g. melanosis 
of the brain parenchyma and leptomeninges), with develop-
ment of symptomatic neurocutaneous melanocytosis in 6% to 
11% of patients with a giant CMN. The association of a giant 
CMN or two medium-sized nevi, with multiple satellite nevi 
and neurocongenital melanosis, constitutes the congenital 
melanocytic nevus syndrome.23 NRAS mutations are identi-
fied in up to 80% of the giant CMN, and are almost universal 
when the PAS is >60 cm.25 Moreover, it has been suggested 
that NRAS mosaicism, in particular postzygotic mutations in 
codon 61, is associated with the onset of neurocutaneous 
melanocytosis. Mutations in BRAF occur in approximately 5% 
–15% of small CMN.9,26 The presence of MC1R variants has 
been associated with increased frequency and size of CMN.9 
The overall risk of malignant transformation of a CMN 
of any size is estimated to be less than 1%. It varies substan-
tially depending on the nevus size and number of nevi, va-
rying from the almost null risk of a common acquired nevus, 
in a single small CMN, to a lifetime risk of 10% –15%, in 
giant CMN with satellite lesions.9,23 UVR is likely to have no 
role in the malignant transformation.9,23 A meta-analysis, 
including a total of 2578 patients (432 patients with giant 
CMN), showed that only 2% of the patients developed mela-
noma and, within this group, 74% had CMN >40 cm (PAS) 
and 94% had satellite lesions.3 In a prospective study, which 
followed 57 patients with giant CMN, the patients that suffe-
red malignant transformation presented with a giant CMN 
in an axial location, with more than 50 satellite lesions.24 
CMN-melanoma may arise from leptomeningeal or brain 
parenchymal melanocytic deposits.27 Primary CNS melano-
mas account for 33% to 50% of all melanomas occurring 
in patients with giant CMN.23,27,28 Kinsler et al followed 450 
patients with multiple CMN, of whom ten developed melano-
ma, seven within CNS. The incidence of melanoma (of any 
location) in children with CMN > 60 cm (PAS) was 8%, and 
only 1% in the other phenotypic groups.23 The strongest sta-
tistical predictor of melanoma development was an abnor-
mal CNS screening with magnetic resonance imaging (MRI), 
which was performed in all patients within the first year of 
life. About 12% of the children with abnormal CNS features 
developed melanoma, contrasting with only 1% in those with 
a normal MRI.23
2.2.2 Diagnosis
During the long-term follow-up, it is of key importance 
to distinguish malignant proliferations from benign growths 
within CMN. Two benign clinical presentations are identified: 
classic proliferative nodules and neuroid overgrowth.26 Ove-
rall, classic proliferative nodules have a well-defined edge, 
a round outline and a smooth surface, often lighter than the 
surrounding CMN. They tend to grow over a period of weeks 
and then stabilize, normally not exceeding 2 cm. On his-
tology, there is no necrosis, low cytological atypia and no 
increased proliferative activity. Neuroid overgrowth areas 
have poorly defined edges, usually ovoid and have a soft 
consistency. Normally, they are not present at birth, but can 
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develop at any point in childhood and their expansion may 
take several years, with the potential to reach over 20 cm. 
Pathologically, they are characterized by nodules of spindle 
cells within a myxoid stroma, without significant atypia.23 
Melanoma arising in giant CMN often presents as a ra-
pidly growing nodule arising in the deep dermis or subcuta-
neous tissues.9,13,23 Dermoscopy is not as helpful as in other 
suspicious lesions.23 In the presence of clinical suspicion, 
an urgent biopsy is mandatory to rule out melanoma. On 
histology, the presence of high-grade nuclear atypia, high 
mitotic activity, ulceration and necrosis can be interpreted 
as suggestive of melanoma.9 Immunohistochemistry of his-
tologically-benign and atypical proliferative nodules in CMN 
found that Ki67 and phosphohistone H3 staining is useful 
to identify the malignant lesions.29 NRAS and BRAF hotspot 
genotyping is recommended to improve diagnostic accuracy 
and to guide management, since most CMN-melanomas are 
NRAS mutated, and BRAF inhibitors are contraindicated in 
NRAS-mutated melanomas due their paradoxical activation 
of RAS.23 
2.2.3 Management
Currently, routine monitoring is not recommended if only 
a single CMN is present. On the other hand, performing 
a clinical follow-up of children with multiple CMN or giant 
CMN is controversial, as the outcomes are apparently not 
better when comparing to those without follow-up. This is 
related to the difficulty in the detection of malignant trans-
formations in giant CMN. Moreover, CMN melanomas are 
considered highly aggressive and its treatment offers less be-
nefit than in other melanoma subtypes.23,30 However, routine 
evaluation is often performed, as the patients may benefit 
from optimized skincare, interdisciplinary follow-up and also 
for reassurance of the family.23 Kinsler et al, recommends to 
perform a whole brain and spine MRI with gadolinium con-
trast, under the age of 1 year (< 6 months ideally) for pa-
tients with two CMN at birth, independently of size or site.23,31 
The rationale is to perform this screening exam before the 
completion of CNS myelination process, which may difficult 
the visualization of the characteristic signs of melanin. If the 
scanning is normal, it does not need to be repeated. In the 
presence of MRI abnormalities, regular clinical and/or radio-
logical monitoring is needed, as there is a higher incidence 
of melanoma, neurodevelopmental abnormalities and epi-
lepsy in the long-term.23
Routine surgical excision of CMN has no evidence of 
changing melanoma risk.23 Complete nevus excision, with 
removal of all deeper tissue layers, would only be beneficial 
in patients with a PAS > 60 cm or for those with MRI abnor-
malities. Even for these patients, the nevus excision would 
only protect a limited proportion of patients, given their high 
risk of developing CNS melanoma.28 If a cutaneous melano-
ma is suspected, wide local excision must be performed and 
subsequent treatment should be guided by a multidiscipli-
nary tumor board, given its highly aggressive behavior and 
poor overall prognosis.
2.3 Conventional Melanoma
2.3.1 Epidemiology and pathogenesis
Approximately 40%–60% of pediatric melanomas are 
considered conventional or adult-type melanoma, since they 
share a similar natural history and histologic subtypes with 
melanomas found in adults.1,2,9,10 Albeit rare among children 
(<11 years), they’re the most common subtype in the adoles-
cent population (11–19 years). The risk factors and baseline 
characteristics are also distinct between those age groups. 
Younger patients are more likely to be ethnically diverse, have 
a personal history of noncutaneous cancer, and develop le-
sions on the head and neck. For adolescents, risk factors in-
clude light skin, UVR exposure and increasing age, following 
the adult trend, reflecting biological mechanisms and cultural 
practices (sunburns and indoor tanning habits).10,13
Genomic studies have shown a high burden of single-nu-
cleotide mutations, consistent with ultraviolet-induced dama-
ge, alongside with the strong prevalence of BRAF and TERT 
promoter mutations. Studies on familial melanoma found 
that germline mutations in CDKN2A or CDK4 are found in 
up to 40% of familial melanomas.9,32 The prevalence of these 
mutations is much lower (<5%) when analyzing all pedia-
tric melanomas.13 Mutations in both genes are associated 
with a clinical phenotype characterized by numerous atypical 
nevi and an increased frequency of multiple primary mela-
nomas.9 The role of MC1R is also subject of investigation. It 
has been proposed that MC1R variants could be an inherited 
susceptibility factor, predisposing to BRAF-mutated melano-
mas, after minimal sun damage in early life.9,33 An asso-
ciation between MC1R variants and melanomas in patients 
younger than 40 years old, was established.9 
2.3.2 Diagnosis
The clinical presentation of melanomas in children can 
be quite non-specific.13,12 Compared with adults, children 
present with thicker primary lesions, often nodular and ame-
lanotic and atypical vascular or crystalline structures can be 
seen on dermoscopy. As said before, pediatric melanomas 
do not fulfill the traditional ABCDE criteria.13 However, for 
pigmented and macular lesions, a dermoscopy devoid of 
benign patterns alongside with the presence of melanoma-
-specific structures increased the likehood of melanoma, just 
as in adults.9 The most common histologic subtypes are, by 
far, the superficial spreading and the nodular. In contrast 
with the adult melanoma, a substantial proportion of these 
neoplasms arise from pre-existing nevus (80%).9 
2.3.3 Management
Globally, the management of conventional pediatric me-
lanoma follows the adult melanoma guidelines. Details on the 
treatment are included in section “3. Melanoma treatment”.
2.4 Congenital melanoma
Melanomas are denominated congenital when diagnosed 
in utero or at birth.3,34 There are three different ways in which 
congenital melanomas can be formed. In the first, melanoma 
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metastasis migrate through the placentae to the fetus, leading 
to widespread visceral involvement and usually death of the 
neonate.34 In mothers with metastatic melanoma that manage 
to give birth, the placentae should be sent to histopathological 
and immunohistochemical evaluation and searched for metas-
tasis. The second way is a form of melanoma de novo or in as-
sociation with a small congenital nevus that has developed in 
uterus. There is also a third form of congenital melanoma that 
is similar to melanoma arising in giant CMN. All of these are 
exceptional clinical situations which do not constitute different 
subtypes of melanoma.
3. MELANOMA TREATMENT
At the present day, there is a lack of consensus on the ma-
nagement of pediatric melanoma and therapeutic approaches 
have been based on the established guidelines for adults.9,10,13 
Local wide excision of primary cutaneous melanoma, with 
adult-based margins, is the  treatment cornerstone.10 However, 
due to the anatomical and functional impact, it is not possi-
ble to achieve such margins in all situations. When compa-
ring pediatric with adult melanomas with the same thickness, 
lower risk of local recurrence has been reported in children.9,10 
Following wide excision, SLNB is usually performed in all ulce-
rated tumors and those thicker than ≥0.8 mm.10 The prognos-
tic value of SLNB is less clear than in adults. A study reviewing 
310 cases of pediatric melanoma who were submitted to SLNB 
reported that melanoma-specific-survival was not improved 
in such cases, when matching with a control group.35 It also 
compared pediatric and adult patients with microscopic nodal 
disease, reporting better survival rates in the former.35 Moreo-
ver, the melanoma subtype deeply influences the rates of SLNB 
positivity, without clear impact on the outcome, as is the case 
in Spitzoid melanomas.22 For patients with clinically-evident 
regional lymph node metastases, complete lymph node dis-
section (CLND) is indicated.10 However, when managing a po-
sitive SLNB in the absence of clinically or radiologically-evident 
nodal metastases, an “observation only” approach is recom-
mended in most cases.36 
Systemic therapy is indicated for patients with regionally 
advanced or distant metastatic disease.10 Evidence-based re-
gimens are currently scarce, both due to its rarity and to the 
exclusion of pediatric patients in most prospective trials. Cur-
rent treatment strategies are therefore extrapolated from adult 
data. Adjuvant therapy has been reserved for patients with lo-
calized disease at increased risk for dissemination. High-dose 
interferon is an option for stage IIB and III melanoma, since it 
has been showed to improve recurrence free survival. The use 
of adjuvant IFNα-2b in children appears to be safe and it is 
better tolerated than in adults.37 In recent years multiple novel 
agents have been approved for the treatment of metastatic me-
lanoma, with promising results. Ipilimumab is a monoclonal 
antibody directed against a T-cell receptor antigen (CTLA-4). 
Its safety in adolescents was demonstrated in a phase I study, 
and a current phase II study is underway.10 Pembrolizumab and 
nivolumab are checkpoint inhibitors of the T-Cell-PD-1 recep-
tors and tumor PDL-1 ligand pathway, and their efficacy and 
tolerability in children are also being studied. Another pathway 
that has been a target for novel treatments is the signaling 
kinase BRAFV6001 activating mutation, (e.g. vemurafenib). Si-
milarly to the previously described treatments, it has been ap-
proved for treating adults, while its effects are currently being 
studied within the pediatric population. MEK1 and MEK2 inhi-
bitors (e.g. trametinib) constitute another agents approved to 
treat BRAF-mutated melanomas in adults.10 The use of MEK 
inhibition has already been employed to control symptoms in 
NRAS-mutated primary CNS melanomas, with positives outco-
mes.38 MEK inhibition has a promising role in the treatment of 
giant CMNs and to prevent its risk of malignant transforma-
tion, although it has not yet moved on to clinical trials.39,40 KIT 
mutations occur in 10% of adult melanoma and kinase inhibi-
tors have potential responses in 15% to 50%.41
Overall, patients must be selected through molecular pro-
filing in order to evaluate the presence of the previously des-
cribed mutations, since the effectiveness of these drugs is null 
in patients without them.10,41 Data from case series and case 
reports, in which these agents have been employed, shows si-
milar results between pediatric and adult patients. 
4. CONCLUSION
Pediatric melanoma fortunately remains rare. When con-
sidering this disease, it is imperative to consider its three main 
subtypes as they’re morphological and biologically different. 
Spitzoid melanoma is the most common subtype affecting 
children younger than 11 years and it encompasses the most 
favorable prognosis. Its pathological diagnosis can be chal-
lenging, since it may share overlapping features with atypical 
Spitzoid tumors. Melanomas arising from congenital nevi are 
rarer than Spitzoid melanoma, but are likely to be responsible 
for most melanoma-related deaths in childhood. This is due 
to the difficult surveillance and treatment, and also to the as-
sociated emergence of CNS melanoma. In adolescents, the 
most common subtype is the conventional (adult-type) mela-
noma, arising mostly from previous nevi and in relation to sun 
exposure and lower phototypes. This stresses the paramount 
importance of the education to the potential hazards of tan-
ning beds and unprotected sun exposure.13 The management 
and treatment of pediatric melanoma follows the adult gui-
delines. Almost all the systemic treatments of advanced/me-
tastatic disease are off-label in pediatrics, although trials are 
underway. Even though it is a rare disease, there have been 
continuous efforts and advances in understanding the genetics 
and molecular processes underlying the emergence of pedia-
tric melanoma, in order to achieve an earlier diagnosis and a 
more suitable treatment.
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Educação Médica Contínua
1.  Which of the following statements is incorrect 
about Pediatric Melanoma?
a) It is the most common skin cancer in the pediatric 
population.
b) Its incidence among children under 11 is lower 
than among adolescents.
c) The average age of diagnosis is about 13 years.
d) Familial cases account for 10% of pediatric mela-
nomas. 
e) There are no considerable sex and ethnic-ba-
sed differences in the incidence of melanoma in 
young children. 
 
2. About Spitzoid melanoma, which of the 
following statements is correct?
a) Although Spitzoid tumors can affect all age 
groups, they usually arise during adulthood;
b) The following dermoscopic patterns are sugges-
tive of a Spitz nevus: starburst pattern, regular-
ly distributed dotted vessels and globular pattern 
with reticular depigmentation;
c) It encompasses a poor prognosis;
d) BRAF or NRAS mutations are typically present in 
Spitzoid tumors
e) On the moment of diagnosis, nodal involvement 
is rare.
 
3. Considering the management of melanoma 
arising in congenital melanocytic nevi, indi-
cate the correct statement. 
a) Routine monitoring is recommended if a child has 
a medium-size congenital melanocytic nevus;
b) There is a tendency towards better outcomes in a 
patient with multiple congenital melanocytic nevi 
who is routinely monitored;
c) A MRI with gadolinium contrast is reccomended, 
under the age of 1 year, for patients with two 
CMN at birth, if at least one is a giant melano-
cytic nevus;
d) Complete nevus excision, with removal of all dee-
per tissue layers, in patients with PAS > 60 cm or 
for those with MRI abnormalities, eliminates the 
risk of melanoma emergence;
e) Routine surgical excision of CMN has no evidence 
of changing melanoma risk.
 
4. Conventional (adult-type melanoma) is the 
most common melanoma in adolescents. 
About this topic, which of the following affir-
mations is false?  
a) Similarly with the adult melanoma, only 25%-
33% of these neoplasmas arise from pre-existing 
nevus;
b) Young patients are more likely to be ethnically di-
verse, have a personal history of noncutaneous 
cancer, and develop lesions on the head and 
neck;
c) Genomic studies show a high burden of single-
-nucleotide mutations consistent with UV-induced 
damage;
d) Mutations in CDKN2A or CDK4 are associated 
with a clinical phenotype characterized by nume-
rous atypical nevi and an increased frequency of 
multiple primary melanomas;
e) The most common histologic subtypes are the su-
perficial spreading and the nodular.
5. About the management and treatment of pe-
diatric melanoma, which of the following sta-
tement is incorrect?  
a) There is a lack of significant evidence in order to 
establish pediatric specific guidelines;
b) A lower risk of local recurrence has been reported 
in the pediatric patients;
c) The value of sentinel lymph node biopsy is well 
established in pediatric patients;
d) The safety and tolerability of adjuvant IFNα-2b in 
children has been verified;
e) When managing a positive SLNB in the absence 
of clinically or radiologically-evident nodal me-
tastases, an “observation only” approach can be 
recommended.
TEST YOURSELF
Key: 1d; 2b; 3e; 4a; 5c.
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